Effects of statins on triglyceride metabolism

The American Journal of Cardiology
H N Ginsberg

Abstract

Hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or "statins," have been extremely efficacious in decreasing low-density lipoprotein (LDL) cholesterol levels in patients with hypercholesterolemia and in treating patients with dysbetalipoproteinemia, a relatively rare form of hyperlipidemia. Clinical trials have indicated that statins can significantly lower very-low-density lipoprotein (VLDL) triglyceride levels, although the central mechanism of action of statins-i.e., increasing the number of LDL receptors-would appear to suggest that they would have no significant effect on VLDL levels. Through a review of published data from animal and human studies, this article addresses the important clinical question of how drugs that inhibit the rate-limiting enzyme for cholesterol can affect triglyceride metabolism.

References

Mar 15, 1989·The Biochemical Journal·B KhanM Heimberg
Feb 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·J M LopezT F Osborne
Feb 15, 1996·Biochemical and Biophysical Research Communications·Y KawabeT Kodama
Apr 4, 1998·The American Journal of Cardiology·G L Vega, S M Grundy
Apr 4, 1998·The American Journal of Cardiology·E A SteinP Laskarzewski

❮ Previous
Next ❯

Citations

Apr 20, 2005·Lipids in Health and Disease·Daniel Favre, Beat Muellhaupt
Apr 23, 2004·Current Neurology and Neuroscience Reports·Olaf StüveScott S Zamvil
Oct 9, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Martin S WeberScott S Zamvil
Apr 4, 2007·Digestive Diseases and Sciences·Masanori YamatoTetsuo Arakawa
Jun 22, 1999·Clinical Cardiology·D B Hunninghake
Nov 17, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Wenxian Wang, Chi-Wai Wong
Jun 20, 2001·Diabetes, Obesity & Metabolism·J R Burnett, G F Watts
Jun 13, 2002·European Journal of Clinical Investigation·A-L García-OtínUNKNOWN ATOMIX Study Group. Atorvastatin in Mixed dyslipidemia
Sep 24, 2008·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·V G Sandhya, T Rajamohan
Jul 4, 2008·Atherosclerosis. Supplements·A AlipourM Castro Cabezas
Nov 16, 2010·Helicobacter·William NseirNimer Assy
Sep 18, 2009·Annals of the New York Academy of Sciences·Pratibha SinghFranz Blaes
Sep 23, 2003·Expert Opinion on Therapeutic Targets·Olaf StüveScott S Zamvil
Jul 25, 2006·Journal of Neuroimmunology·Martin S WeberScott S Zamvil
Mar 22, 2014·Journal of Evidence-based Complementary & Alternative Medicine·Charu KatareG B K S Prasad
Dec 18, 2016·Circulation·Gissette Reyes-SofferHenry N Ginsberg
Aug 14, 2002·American Journal of Pharmacogenomics : Genomics-related Research in Drug Development and Clinical Practice·S C FrancisM K Raizada
Aug 26, 2006·Nature Clinical Practice. Neurology·Martin S WeberScott S Zamvil
May 7, 2008·Expert Review of Neurotherapeutics·Maurizio BifulcoGiuseppe Marasco
Jul 30, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Laura TrapaniValentina Pallottini
Dec 23, 2004·Journal of Cardiovascular Pharmacology·Dianne J M DelsingHans M G Princen
Feb 20, 2020·Journal of Applied Toxicology : JAT·Patrícia Villela E SilvaWilma De Grava Kempinas
Mar 13, 1999·Current Opinion in Lipidology·A Ogunko, M Evans
Jun 2, 2020·Frontiers in Endocrinology·Chris J PackardMarja-Riitta Taskinen
Jun 14, 2003·The Neurologist·Olaf StüveScott S Zamvil
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·I J JonkersA van der Laarse
Aug 5, 2000·American Heart Journal·M Miller
Sep 29, 2001·The American Journal of Cardiology·H N Ginsberg, D R Illingworth
Feb 7, 2001·Journal of the American Society of Nephrology : JASN·Christopher J DeighanChristopher J Packard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.